Shopping Cart

Your shopping cart is currently empty

WITHAFERIN A

Name: WITHAFERIN A
Brand: TargetMol
SKU: T5687
Price: 77 USD
Availability: InStock
Rating: 5 (10 reviews)

Copy Product Info

😃Good

Catalog No. T5687Cas No. 5119-48-2

WITHAFERIN A is a novel class of NFkappaB inhibitors, which hold promise as novel anti-inflammatory agents for treatment of various inflammatory disorders and/or cancer.

WITHAFERIN A

Copy Product Info

😃Good

Purity: 99.99%

Catalog No. T5687Cas No. 5119-48-2

WITHAFERIN A is a novel class of NFkappaB inhibitors, which hold promise as novel anti-inflammatory agents for treatment of various inflammatory disorders and/or cancer.

Pack Size	Price	USA Warehouse	Global Warehouse
1 mg	$77	In Stock	In Stock
5 mg	$279	In Stock	In Stock
10 mg	$413	In Stock	In Stock
25 mg	$688	In Stock	In Stock
50 mg	$978	In Stock	In Stock
100 mg	$1,320	In Stock	In Stock
500 mg	$2,650	-	In Stock
1 mL x 10 mM (in DMSO)	$319	In Stock	In Stock

Add to Cart

Add to Quotation

In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]

All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Questions

Batch Information

Select Batch

Purity:99.99%

Color:White

Resource Download

COA HNMR LCMS

Product Introduction

Bioactivity

Description	WITHAFERIN A is a novel class of NFkappaB inhibitors, which hold promise as novel anti-inflammatory agents for treatment of various inflammatory disorders and/or cancer.
In vitro	WITHAFERIN A,potently inhibits NFkappaB activation by preventing the tumor necrosis factor-induced activation of IkappaB kinase beta via a thioalkylation-sensitive redox mechanism.
In vivo	WITHAFERIN A Displays Anti-inflammatory Properties in Vivo—Because NFκB is a critical player in the inflammatory signaling pathway and because WITHAFERIN A inhibits NFκB activation.
Cell Research	L929sA cells were co-treated with WITHAFERIN A and DTT for 1 h, and then TNF-induced NFκB activation was examined.
Animal Research	Mice are injected subcutaneously with zymosan in the footpad, and swelling is determined at several time points after the injection. Pretreatment with WITHAFERIN A(intraperitoneal) was performed to evaluate anti-inflammatory effects, whereas DEX (intraperitoneal) was chosen as a positive control. the mean of the differences between the zymosan-treated and untreated footpad for all the three groups. Both DEX.

Chemical Properties

Molecular Weight	470.60
Formula	C₂₈H₃₈O₆
Cas No.	5119-48-2
Smiles	C[C@@H]([C@H]1CC[C@H]2[C@@H]3C[C@H]4O[C@]44[C@@H](O)C=CC(=O)[C@]4(C)[C@H]3CC[C@]12C)[C@H]1CC(C)=C(CO)C(=O)O1
Relative Density.	1.28g/cm3

Storage & Solubility Information

Storage

In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

Solubility Information

DMSO: 50.50 mg/mL (107.31 mM), Sonication is recommended.

In Vivo Formulation

10% DMSO+40% PEG300+5% Tween-80+45% Saline: 0.5 mg/mL (1.06 mM), Sonication is recommended.

Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.

Solution Preparation Table

DMSO

	1mg	5mg	10mg	50mg
1 mM	2.1249 mL	10.6247 mL	21.2495 mL	106.2473 mL
5 mM	0.4250 mL	2.1249 mL	4.2499 mL	21.2495 mL
10 mM	0.2125 mL	1.0625 mL	2.1249 mL	10.6247 mL
20 mM	0.1062 mL	0.5312 mL	1.0625 mL	5.3124 mL
50 mM	0.0425 mL	0.2125 mL	0.4250 mL	2.1249 mL
100 mM	0.0212 mL	0.1062 mL	0.2125 mL	1.0625 mL

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments

and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent

10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO TargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO TargetMol | reagent stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH₂O TargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc